MedPath

Azelastine Hydrochloride

AZELASTINE nasal spray Initial U.S. Approval: 1996

Approved
Approval ID

02257284-4bb1-4fe6-8134-e5a67a645114

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 4, 2023

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

azelastine hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50090-2330
Application NumberANDA077954
Product Classification
M
Marketing Category
C73584
G
Generic Name
azelastine hydrochloride
Product Specifications
Route of AdministrationNASAL
Effective DateNovember 17, 2022
FDA Product Classification

INGREDIENTS (8)

EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT
AZELASTINE HYDROCHLORIDEActive
Quantity: 137 ug in 1 1
Code: 0L591QR10I
Classification: ACTIB
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORMInactive
Code: GR686LBA74
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.